Article (Scientific journals)
Rubus idaeus extract improves symptoms in knee osteoarthritis patients: results from a phase II double-blind randomized controlled trial.
Henrotin, Yves; Cozannet, Romain Le; Fança-Berthon, Pascale et al.
2022In BMC Musculoskeletal Disorders, 23 (1), p. 650
Peer Reviewed verified by ORBi
 

Files


Full Text
Henrotin et al Rubus Idaeus BMC Musculoskeletal disorders 2022.pdf
Author postprint (1.49 MB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Clinical trial; Knee; Osteoarthritis; Pain; Rubus idaeus; Plant Extracts; Aged; Double-Blind Method; Humans; Pain/diagnosis; Pain/drug therapy; Pain/etiology; Plant Extracts/adverse effects; Treatment Outcome; Osteoarthritis, Knee/diagnosis; Osteoarthritis, Knee/drug therapy; Rubus; Osteoarthritis, Knee; Rheumatology; Orthopedics and Sports Medicine
Abstract :
[en] ("[en] BACKGROUND: Osteoarthritis (OA) is the most frequent cause of disability in elderly people. In daily practice, the main objective of the physician is to reduce patient symptoms using treatments without adverse effects. However, the most prescribed treatment to manage OA symptoms remains nonsteroidal anti-inflammatory drugs which are associated with severe adverse effects. Therefore, we need a safe alternative to managing OA. One candidate is Rubus idaeus leaf extracts known to inhibit inflammatory responses. OBJECTIVE: This study aimed to evaluate the effects of a 12-weeks intervention with an ethanolic extract from Rubus idaeus leaf on symptoms of knee osteoarthritis. METHOD: The study was a randomized, double-blind, placebo-controlled, monocentric trial of 198 participants with femorotibial osteoarthritis. Participants were randomized equally to receive one daily during 3 months either 1 capsule of Rubus idaeus leaf extract 400 mg, 1 capsule of Rubus idaeus leaf extract 200 mg, or 1 capsule of placebo. The participants were assessed at baseline and after one and three months of treatment. The primary endpoint was an absolute change of the Western Ontario McMaster osteoarthritis index (WOMAC) pain subscale. The secondary endpoints were WOMAC global score, stiffness and function sub-scales, knee pain VAS score at walking, the Short Form (SF)-36, the Short Physical Performance Battery (SPPB), the 20-m walk test, and the International Physical Activity Questionnaire (IPAQ) and Outcome Measures in Rheumatology Clinical Trials and Osteoarthritis Research Society International (OMERACT-OARSI) responders rate. Statistical analyses were conducted on the intent-to-treat (ITT) population. RESULTS: In the Intention-to-treat population, WOMAC pain was not significantly modified by Rubus idaeus leaf extract compared to placebo. In contrast, Rubus idaeus leaf extract 400 mg after 12 weeks of treatment significantly reduced pain measured by the VAS. The mean pain decrease induced by Rubus ideaus leaf extract was over -7 mm which is clinically relevant and reached a clinically statistical difference compared to placebo with the highest dose. Rubus Ideaus was not significantly more efficient than the placebo on WOMAC global score, stiffness, and physical function subscores, IPAQ, SF-36, walking distance in treadmill test, SPPB, and evaluation of associated treatments needed to manage OA. CONCLUSION: Rubus idaeus leaf extract was well tolerated and effective to relieve pain in a patient with knee osteoarthritis. TRIAL REGISTRATION: NCT03703024  (11/10/2018).","[en] ","")
Disciplines :
Rheumatology
Author, co-author :
Henrotin, Yves  ;  Université de Liège - ULiège > Département des sciences de la motricité > Pathologie générale et physiopathologie - Techniques particulières de kinésithérapie
Cozannet, Romain Le;  Naturex SA, Avignon, France
Fança-Berthon, Pascale;  Naturex SA, Avignon, France
Truillet, Romain;  Atlanstat SA, Les Espaces Océane, 3, rue Jules Verne, 44400, Rezé, France
Cohen-Solhal, Martine;  BIOSCAR Inserm U1132 and Department of Rheumatology, Université de Paris, Hôpital 10 Lariboisière, 75010, Paris, France
DunnGalvin, Gillian;  Atlantia Clinical Trials, Heron House Offices, Blackpool, T23 R50R, Cork, Ireland
Grouin, Jean-Marie;  Department of Statistics, Rouen University, Rouen, France
Doolan, Andrea;  Atlantia Clinical Trials, Heron House Offices, Blackpool, T23 R50R, Cork, Ireland
Language :
English
Title :
Rubus idaeus extract improves symptoms in knee osteoarthritis patients: results from a phase II double-blind randomized controlled trial.
Publication date :
07 July 2022
Journal title :
BMC Musculoskeletal Disorders
eISSN :
1471-2474
Publisher :
BioMed Central Ltd, England
Volume :
23
Issue :
1
Pages :
650
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 11 February 2023

Statistics


Number of views
82 (6 by ULiège)
Number of downloads
27 (2 by ULiège)

Scopus citations®
 
2
Scopus citations®
without self-citations
2
OpenCitations
 
0
OpenAlex citations
 
2

Bibliography


Similar publications



Contact ORBi